In an AsPC‐1 subcutaneous xenograft study, compared with controls, mean tumour weight after 2‐week therapy decreased by 50% with NPT+Gem (P = 0.001), 20% with αMMP9 (P = 0.136) and 63% with NPT+Gem+αMMP9 (P = 0.0006) (Figure 6A). The gene discussed is GEM; the disease is neoplasm.